Key terms
About RGEN
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RGEN news
Apr 08
9:45pm ET
RBC Capital Remains a Buy on Repligen (RGEN)
Mar 25
2:05pm ET
Ingersoll-Rand’s Dover deal not a threat to bioprocessing space, says KeyBanc
Mar 19
7:52am ET
Repligen Corp Announces Board Appointment and Compensation Plan
Mar 19
7:35am ET
Repligen appoints Pax to board of directors
Feb 26
12:10am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)
Feb 23
9:14am ET
Repligen price target raised to $225 from $175 at Craig-Hallum
Feb 22
8:58am ET
Repligen price target raised to $207 from $165 at Stifel
Feb 22
8:17am ET
Repligen (RGEN) Receives a Buy from Stifel Nicolaus
Feb 22
7:31am ET
Repligen (RGEN) Receives a Buy from RBC Capital
Feb 21
7:34am ET
Repligen reports Q4 adjusted EPS 33c, consensus 33c
Feb 20
8:39am ET
Repligen (RGEN) Gets a Buy from Craig-Hallum
Feb 15
8:46am ET
Craig-Hallum Remains a Buy on Repligen (RGEN)
Feb 15
6:44am ET
Repligen price target raised to $220 from $210 at KeyBanc
Jan 26
8:46pm ET
RBC Capital Sticks to Their Buy Rating for Repligen (RGEN)
No recent press releases are available for RGEN
RGEN Financials
Key terms
Ad Feedback
RGEN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RGEN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
